Having placed executives into these roles repeatedly, we wrote this to tell you what genuinely matters, not the generic career advice you have already read. Restrictive covenants are common in pharmaceutical employment, where companies protect scientific information, regulatory strategy, and customer relationships, and they can shape which moves are available to you. This is general information rather than legal advice, and because enforceability varies substantially by jurisdiction and the law in this area has been changing, you should have an employment attorney review your specific agreement.
Key Takeaways
- Pharmaceutical agreements often contain several distinct restrictions.
- Confidentiality and non-solicit terms may constrain more than the non-compete.
- Enforceability varies by jurisdiction and has been changing.
- Negotiate scope and duration before joining, when leverage exists.
- Disclose existing agreements to employers and recruiters early.
What These Agreements Usually Contain
Pharmaceutical employment agreements typically bundle several distinct provisions that candidates often treat as one. A non-compete restricts working for defined competitors for a period. A non-solicit restricts recruiting former colleagues or, separately, approaching customers. Confidentiality provisions protect scientific, regulatory, and commercial information, often without time limit. Invention assignment provisions govern intellectual property. These operate independently, and in practice the confidentiality and non-solicit terms frequently constrain a move more than the non-compete, particularly for scientific and commercial roles.
Enforceability Is Genuinely Variable
How enforceable a restriction is depends on jurisdiction, the specific terms, the seniority and nature of the role, and the circumstances of departure. Some jurisdictions substantially limit or prohibit non-competes, others enforce those they consider reasonable, and reasonableness in duration, geographic scope, and definition of competitor is often assessed case by case. The regulatory and legal position has also been actively evolving. General assumptions are therefore unreliable in either direction, and only advice specific to your agreement and jurisdiction provides a sound basis for decisions.
Negotiate Before You Sign
Leverage over these terms is highest before you accept an offer, when the agreement is a draft and the company wants you. Candidates frequently sign without reading, then discover the constraints years later when they matter most. Requesting the full agreement during the offer process, having it reviewed, and proposing modifications, narrowing the competitor definition, shortening the period, limiting geography, clarifying treatment on termination without cause, is entirely normal, and companies often accommodate reasonable requests from candidates they are trying to hire.
Disclose Early When Moving
If you are already bound and considering a move, tell prospective employers and search consultants early rather than after an offer. Pharmaceutical companies deal with this constantly and frequently structure roles to avoid conflict, adjusting scope, therapeutic area, geography, or start timing. Concealment until late creates serious problems for everyone and can lose you the role. Get your own advice on what the agreement actually restricts before deciding what to pursue, since candidates frequently assume either broader or narrower constraints than the document imposes.
Scientific Information Deserves Particular Care
In pharmaceutical roles, confidentiality obligations around scientific and regulatory information are substantive and typically survive employment indefinitely. Even where a non-compete is unenforceable, using or disclosing a former employer’s confidential scientific data, regulatory strategy, or trade secrets creates genuine exposure. Practically, this means being deliberate about what you carry, in documents and in what you say, and being clear with a new employer about what you cannot contribute. Employers who pressure you toward disclosing a former employer’s confidential information are creating risk for you as well as themselves.
What This Looks Like in Practice
A pharmaceutical professional reads the full agreement before accepting, has it reviewed by an employment attorney, negotiates competitor definition, duration, and geography while leverage exists, discloses existing agreements early to prospective employers and recruiters, and is deliberate about confidential scientific information regardless of non-compete enforceability.
The Mistake Candidates Keep Making
The most common mistake is signing without reading and then, years later, making career decisions on assumptions about a document never reviewed and law never checked, concluding either that the agreement does not apply or that it blocks everything. Both errors are common and both are avoidable through specific advice on the actual agreement.
Provisions and Their Practical Effect
| Provision | Typical Practical Effect |
|---|---|
| Non-compete | Limits work for defined competitors for a period |
| Employee non-solicit | Restricts recruiting former colleagues |
| Customer non-solicit | Often the binding constraint in commercial roles |
| Confidentiality | Protects scientific and regulatory information, often indefinitely |
| Invention assignment | Governs ownership of work created during employment |
The Bottom Line
Pharmaceutical restrictive covenants bundle several independent provisions, with confidentiality and non-solicit terms often constraining more than the non-compete, so read and negotiate before signing, disclose existing agreements early, treat confidential scientific information carefully regardless of enforceability, and get advice from an employment attorney on your specific agreement and jurisdiction. Be deliberate about this, and you will be choosing between offers rather than hoping for one.
Related Reading
For more, see Common Red Flags Pharma Candidates Should Watch For, What Pharma Recruiters Wish Candidates Knew, Relocation Considerations for Pharma Executives.
Frequently Asked Questions
- Q: Are pharmaceutical non-competes enforceable?
- A: It depends substantially on jurisdiction, terms, role, and circumstances, and the law has been changing, so this requires advice from an employment attorney familiar with current local law.
- Q: Which provision constrains most in practice?
- A: Often confidentiality and customer non-solicit terms rather than the non-compete, particularly for scientific and commercial roles where information and relationships are the value.
- Q: When should I negotiate these terms?
- A: Before accepting an offer, when the agreement is a draft and the company wants you, since companies frequently accommodate reasonable requests from candidates they are recruiting.
- Q: What if I am already bound?
- A: Disclose early to prospective employers and recruiters, since pharmaceutical companies routinely structure roles to avoid conflict, and get advice on what the agreement actually restricts.
- Q: Does confidentiality survive an unenforceable non-compete?
- A: Typically yes; obligations around confidential scientific data, regulatory strategy, and trade secrets are independent and often indefinite, so care is warranted regardless.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
